Autopsy report · NCT02985242

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

“difficulties to recruit planned numbers of patients within reasonable time frame”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 1 year 2 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Hannover Medical School

Sponsor type

University, hospital or other

Conditions

Diabetes Mellitus, Type II

Interventions

Empagliflozin; Glimepiride; Empagliflozin placebo; Glimepiride placebo

Participants

6

Sites

1

Countries

Germany

Trials that died the same way

• EXtended Therapy in Hepatitis C Genotype 3 Infected Patients
  “Unlikely to recruit the adequate number of patients within a reasonable timeline” (81% match in meaning)
• Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)
  “Unable to recruit sufficient numbers of patients” (72% match in meaning)
• Prospective Study of the sensiTVT
  “The recruitment proceeded much slower than expected. The planned number of patients could not be reached within the planned time.” (72% match in meaning)
• Mechanistic Prehabilitation
  “difficulty in recruiting patients” (71% match in meaning)
• Does Thiamine Help Vomiting and Nausea in Pregnancy?
  “Difficulties in recruiting patients” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.